Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.


TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a discovery-focused biotechnology company and the development of therapeutic antibodies targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has filed a registration statement on Form 10 (the “Registration Statement” ) with the United States Securities and Exchange Commission (“SEC”) to register the Company’s common stock (the “Common Stock”) under Section 12(b) of the Securities Exchange Act of 1934, as amended, in connection with its application to list its common stock on the Nasdaq Capital Market (“Nasdaq”).

“With this milestone, we are entering the final stages of a transformation of ProMIS that began last year, first with capital formation and now with a potential NASDAQ listing. Our lead therapeutic candidate for Alzheimer’s disease, PMN310, is progressing well and, following written pre-IND comments from the FDA, remains on track for an IND filing by the end of the year,” said Eugene Williams, president and CEO of ProMIS. We remain optimistic that clinical data in the area of ​​Alzheimer’s disease, particularly data from the pivotal trial of Eisai’s lecanemab study, will be positive and may reverse the negative sentiment that has resulted from EMA and CMS decisions regarding Aduhelm. , including ProMIS. We have also expanded and advanced our broader portfolio, continuing to apply the unique capabilities of our technology platform to fight diseases related to misfolded proteins. We believe the Nasdaq, with its tremendous depth and breadth of science-driven investment capital, is the right exchange to fully appreciate the value of ProMIS’ portfolio.

The registration statement relating to the common stock that has been filed with the SEC is subject to the review and comment of the staff of the SEC and there can be no assurance that the registration statement will ultimately be declared effective. The registration statement has also been filed with the Canadian System for Electronic Document Retrieval (“SEDAR”). The registration statement is available on the SEC’s website at www.sec.govon the Company’s SEDAR profile at www.sedar.com and on the Company’s website.

Listing of the Company’s common stock on Nasdaq is subject to satisfaction of Nasdaq’s listing requirements and stock exchange approval of listing. There can be no assurance that the Nasdaq will approve the Company’s listing application in a timely manner, if at all.

About ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a development-stage biotechnology company focused on the discovery and development of therapeutic antibodies that selectively target toxic oligomers implicated in the development and progression of neurodegenerative diseases, particularly Alzheimer’s disease (AD) , amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic and computational discovery platform – ProMIS™ and Collective Coordinates – to predict novel targets known as disease-specific epitopes on the molecular surface of misfolded proteins. Using this unique approach, ProMIS is developing new therapeutic antibodies for AD, ALS and MSA. ProMIS is headquartered in Toronto, Ontario, Canada with offices in Cambridge, Massachusetts, USA. ProMIS is listed on the Toronto Stock Exchange (TSX) under the symbol PMN and on the venture capital market OTCQB under the symbol ARFXF.

Visit us at www.promisneurosciences.comfollow us on Twitter and LinkedIn

For Investor Relations, please contact:Alpine Equity AdvisorsNicholas Rigopulos, Chairman[email protected]Such. 617 901-0785

The TSX has not reviewed and accepts no responsibility for the adequacy or accuracy of this release. Certain information contained in this press release constitutes forward-looking statements and forward-looking information (collectively, “Forward-Looking Information”). within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, transmittingforward-looking information can be identified by the use of forward-looking terminology such as “plans”, “target”, “expects” or “does not expect”, “is expected”, “opportunity exists “, “is positioned”, “believes”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of these words and expressions or declare that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “will occur” or “will be achieved”. expectations, projections or other characterizations of future events or circumstances contains forward-looking information. Specifically, this press release contains forward-looking information relating to the potential effectiveness of the registration statementthe potential timeline for an IND for PMN310, expected data from from Eisai lecanemab studyexpanding our broader portfolio, and the potential listing of the Company’s common stock on Nasdaq. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates.. Important factors that could cause actual results and financial condition to differ materially from those set forth in the forward-looking information include, among others, the factors discussed in the “Risk Factors” section of this Registration statement available at www.sec.gov and the most recently filed annual information form available at www.SEDAR.com. Except as required by applicable securities laws, the Company undertakes no obligation to update publicly any forward-looking information, whether written or oral, which may be made from time to time, whether as a result of new information, future developments or otherwise.##

main logo

Source: ProMIS Neurosciences Inc.